Prevention of Contrast Induced Nephropathy by Erythropoietin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 142 participants.

Also called NCT01364402

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 142 participants (planned count) (from the registry)
Sponsor
Western Galilee Hospital-Nahariya (from the registry)
Registry
  • NCT NCT01364402
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Israel (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01364402. Randomized; quadruple masking; primary purpose prevention. Start 2011-08 (registry gives no type); primary completion 2013-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Prevention of Contrast Induced Nephropathy by Erythropoietin
Condition
Diabetes
Condition
Chronic Kidney Insufficiency
Intervention (Drug)
Epoetin beta
Intervention (Drug)
Saline 0.9%
Lead sponsor
Western Galilee Hospital-Nahariya (class: other government)

Record details

Record id
cardio:ct-nct01364402
Content hash
d8e6aa12ca26a0d4d73979603551ed262d1ca8dcfea7062d94511da01fb3ac01